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2008-2009 Influenza Season 
Week 23 ending June 13, 2009 
All data are preliminary and may change as more reports are received. 
 
On June 11, the World Health Organization raised the pandemic alert level from Phase 5 to Phase 
6 indicating that an influenza pandemic is underway.  The novel influenza A (H1N1) virus now will 
be referred to as “pandemic H1N1 influenza virus.”  
 
Synopsis:  During week 23 (June 7-13, 2009), influenza activity decreased in the United States, 
however, there were still higher levels of influenza-like illness than is normal for this time of year.   
o Two thousand seven hundred sixty-five (38.7%) specimens tested by U.S. World Health 
Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) 
collaborating laboratories and reported to CDC/Influenza Division were positive for influenza. 
o Over 98% of all subtyped influenza A viruses being reported to CDC were pandemic influenza A 
(H1N1) viruses. 
o The proportion of deaths attributed to pneumonia and influenza (P&I) was slightly above the 
epidemic threshold.  
o One influenza-associated pediatric death was reported and was associated with pandemic 
influenza A (H1N1) virus infection. 
o The proportion of outpatient visits for influenza-like illness (ILI) was below the national baseline.  
One of the 10 surveillance regions reported ILI above their region-specific baseline. 
o Eleven states reported geographically widespread influenza activity, six states and Puerto Rico 
reported regional influenza activity, the District of Columbia and 13 states reported local 
influenza activity, and 20 states reported sporadic influenza activity. 
 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative for the season 
HHS 
Surveillance 
Regions* 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity§  
A (H1) A (H3) 
Pandemic 
A (H1N1) 
A  
(could 
not be 
sub-
typed)¥ 
A 
 (Un-
sub-
typed) 
B  Pediatric Deaths 
Nation Normal 38.7% 18 of 52 7,824 2,170 12,316 428 13,079 10,397 71 
Region I Normal 38.3% 4 of 6 520 151 1,542 13 1,302 800 1 
Region II Elevated 35.5% 3 of 3 277 137 592 16 1,492 711 9 
Region III Normal 37.5% 3 of 6 1,313 213 1,353 0 669 1,360 9 
Region IV Normal 19.7% 2 of 8 828 117 351 41 1,897 1,211 6 
Region V Normal 52.6% 2 of 6 1,653 190 5,726 129 555 1,326 11 
Region VI Normal 14.1% 0 of 5 768 165 898 5 4,079 2,608 14 
Region VII Normal 12.0% 0 of 4 498 60 159 113 450 529 0 
Region VIII Normal 29.7% 1 of 6 526 216 745 57 1,501 498 6 
Region IX Normal 12.9% 3 of 4 1,061 627 680 22 798 690 14 
Region X Normal 23.2% 0 of 4 380 294 270 32 336 664 1 
* HHS regions (Region I: CT, ME, MA, NH, RI, VT; Region II: NJ, NY, Puerto Rico, US Virgin Islands; Region III: DE, DC, MD, PA, VA, WV; Region IV: AL, FL, GA, KY, MS, NC, 
SC, TN; Region V: IL, IN, MI, MN, OH, WI; Region VI: AR, LA, NM, OK, TX; Region VII: IA, KS, MO, NE; Region VIII: CO, MT, ND, SD, UT, WY; Region IX: AZ, CA, Guam, HI, 
NV; and Region X: AK, ID, OR, WA) 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline 
‡ National data are for current week; regional data are for the most recent three weeks 
§ Includes all 50 states, the District of Columbia, and Puerto Rico 
¥ The majority of influenza A viruses that cannot be sub-typed as seasonal influenza viruses are pandemic A (H1N1) influenza viruses upon further testing 
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U.S. Virologic Surveillance:  WHO and NREVSS collaborating laboratories located in all 50 states 
and Washington D.C. report to CDC the number of respiratory specimens tested for influenza.  
 
During the 2008-09 season, influenza A (H1), A (H3), and B viruses have co-circulated in the United 
States.  On April 15 and 17, 2009, CDC confirmed the first two cases of pandemic influenza A 
(H1N1) virus in the United States. As of June 19, 2009, 21,449 confirmed and probable infections 
with pandemic influenza A (H1N1) virus and 87 deaths (24 in individuals less than 25 years and 63 
deaths in adults 25 years of age older) have been identified by CDC and state and local public 
health departments.  Reporting of pandemic influenza A (H1N1) viruses by U.S. WHO collaborating 
laboratories began during week 17 (week ending May 2, 2009).  The results of tests performed 
during the current week are summarized in the table below. 
 
 Week 23 
No. of specimens tested 7,149 
No. of positive specimens (%) 2,765 (38.7%) 
Positive specimens by type/subtype  
Influenza A              2,759 (99.8%) 
          A (pandemic H1N1)   2,263 (82.0%)  
          A (subtyping not performed)          429 (15.5%)
          A (unable to subtype) 24 (0.9%)  
          A (H3)                   21 (0.8%) 
          A (H1) 22 (0.8%)
Influenza B                   6 (0.2%) 
 
During week 23, seasonal influenza A (H1), A (H3), and B viruses co-circulated at low levels with 
pandemic influenza A (H1N1).  Over 98% of all subtyped influenza A viruses being reported to CDC 
this week were pandemic influenza A (H1N1) viruses. 
 
The increase in the percentage of specimens testing positive for influenza by WHO and NREVSS 
collaborating laboratories may be due in part to changes in testing practices by health care 
providers, triaging of specimens by public health laboratories, an increase in the number of 
specimens collected from outbreaks, and other factors. 
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Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2008-09 
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Antigenic Characterization:  CDC has antigenically characterized 1,635 seasonal human 
influenza viruses [947 influenza A (H1), 171 influenza A (H3) and 517 influenza B viruses] collected 
by U.S. laboratories since October 1, 2008, and 144 pandemic influenza A (H1N1) viruses. 
All 947 influenza seasonal A (H1) viruses are related to the influenza A (H1N1) component of the 
2008-09 influenza vaccine (A/Brisbane/59/2007).  All 171 influenza A (H3N2) viruses are related 
to the A (H3N2) vaccine component (A/Brisbane/10/2007).  
All 144 pandemic influenza A (H1N1) viruses are related to the A/California/07/2009 (H1N1) 
reference virus selected by WHO as a potential candidate for pandemic influenza A (H1N1) 
vaccine. 
Influenza B viruses currently circulating can be divided into two distinct lineages represented by the 
B/Yamagata/16/88 and B/Victoria/02/87 viruses. Sixty-five influenza B viruses tested belong to the 
B/Yamagata lineage and are related to the vaccine strain (B/Florida/04/2006). The remaining 452 
viruses belong to the B/Victoria lineage and are not related to the vaccine strain.  
Data on antigenic characterization should be interpreted with caution given that antigenic 
characterization data is based on hemagglutination inhibition (HI) testing using a panel of reference 
ferret antisera and results may not correlate with clinical protection against circulating viruses 
provided by influenza vaccination. 
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Annual influenza vaccination is expected to provide the best protection against those virus 
strains that are related to the vaccine strains, but limited to no protection may be expected when the 
vaccine and circulating virus strains are so different as to be from different lineages, as is seen with 
the two lineages of influenza B viruses.  Antigenic characterization of pandemic influenza A (H1N1) 
viruses indicates that these viruses are antigenically and genetically unrelated to seasonal influenza 
A (H1N1) viruses, suggesting that little to no protection would be expected from vaccination with 
seasonal influenza vaccine.  
Antiviral Resistance: Since October 1, 2008, 988 seasonal influenza A (H1N1), 172 influenza A 
(H3N2), and 529 influenza B viruses have been tested for resistance to the neuraminidase 
inhibitors (oseltamivir and zanamivir).  Nine hundred ninety-one seasonal influenza A (H1N1) and 
179 influenza A (H3N2) viruses have been tested for resistance to the adamantanes (amantadine 
and rimantadine).  One hundred eighty-eight pandemic influenza A (H1N1) viruses have been 
tested for resistance to the neuraminidase inhibitors (oseltamivir and zanamivir).  One hundred 
forty-two pandemic influenza A (H1N1) viruses have been tested for resistance to the adamantanes 
(amantadine and rimantadine).  The results of antiviral resistance testing performed on these 
viruses are summarized in the table below. 
 
Resistant Viruses, 
Number (%) 
Resistant 
Viruses, Number 
(%)  Isolates tested (n) 
Oseltamivir Zanamivir 
Isolates 
tested (n) 
Adamantanes 
Seasonal Influenza 
A (H1N1) 988 983 (99.5%) 0 (0) 991 6 (0.6%) 
Influenza A (H3N2) 172 0 (0) 0 (0) 179 179 (100%) 
Influenza B 529 0 (0) 0 (0) N/A* N/A* 
Pandemic 
Influenza A  (H1N1) 188 0 (0) 0 (0) 142 142 (100%) 
*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses. 
 
Antiviral treatment with either oseltamivir or zanamivir is recommended for all patients with 
confirmed, probable or suspected cases of pandemic influenza A (H1N1) virus infection who are 
hospitalized or who are at higher risk for seasonal influenza complications.  The pandemic influenza 
A (H1N1) virus is susceptible to both neuraminidase inhibitor antiviral medications zanamivir and 
oseltamivir.  It is resistant to the adamantane antiviral medications, amantadine and 
rimantadine. Additional information on antiviral recommendations for treatment and 
chemoprophylaxis of pandemic influenza A (H1N1) infection is available at 
http://www.cdc.gov/h1n1flu/recommendations.htm 
 
In areas that continue to have seasonal influenza activity, especially those with circulation of 
oseltamivir-resistant seasonal human influenza A (H1N1) viruses, clinicians might prefer to use 
either zanamivir or a combination of oseltamivir and either rimantadine or amantadine to provide 
adequate empiric treatment or chemoprophylaxis for patients who might have seasonal human 
influenza A (H1N1) virus infection. 
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 23, 7.0% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage is 
slightly above the epidemic threshold of 6.9% for week 23. 
 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
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Influenza-Associated Pediatric Mortality:  One influenza-associated pediatric death was reported 
to CDC during week 23 (Arizona).  This death was associated with a pandemic influenza A (H1N1) 
virus infection.  The death reported this week occurred during week 23 (the week ending June 13, 
2009).  Since September 28, 2008, CDC has received 71 reports of influenza-associated pediatric 
deaths that occurred during the current influenza season, six of which were due to pandemic 
influenza A (H1N1) virus infections.   
 
Of the 34 children who had specimens collected for bacterial culture from normally sterile sites, 14 
(41.2%) were positive; Staphylococcus aureus was identified in nine (64.3%) of the 14 children.  
One of the three children with confirmed pandemic influenza A (H1N1) infection had a specimen 
collected from a normally sterile site; bacterial cultures were negative.  Four of the S. aureus 
isolates were sensitive to methicillin and five were methicillin resistant.   Twelve (85.7%) of the 14 
children with bacterial coinfections were five years of age or older and 10 (71.4%) of the 14 children 
were 12 years of age or older.  An increase in the number of influenza-associated pediatric deaths 
with bacterial coinfections was first recognized during the 2006-07 influenza season.  In January 
2008, interim testing and reporting recommendations were released regarding influenza and 
bacterial coinfections in children and are available at 
(http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00268). 
 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
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Influenza-Associated Hospitalizations:  Laboratory-confirmed influenza-associated 
hospitalizations are monitored in two population-based surveillance networks: the New Vaccine 
Surveillance Network (NVSN) and the Emerging Infections Program (EIP).   
 
During October 12, 2008 to May 30, 2009, the preliminary laboratory-confirmed influenza-
associated hospitalization rate for children 0-4 years old in the NVSN was 3.85 per 10,000. 
Because of case identification methods utilized in this study, there is a delay from the date of 
hospitalization to the date of report.  
 
 
NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children 0 - 4 Years, 2008-09 and Previous Three Seasons 
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During April 15, 2009 – June 13, 2009, the following preliminary laboratory-confirmed overall 
influenza associated hospitalization rates were reported by the EIP (rates include type A, type B, 
and confirmed Pandemic H1N1): 
 
Rates for children aged 0-23 months, 2-4 years, and 5-17 years were 0.92, 0.22, and 0.16 per 
10,000, respectively.  Rates for adults aged 18-49 years, 50-64 years, and ≥ 65 years, the overall 
flu rates were 0.07, 0.09, and 0.23 per 10,000, respectively. 
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EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates, 
Spring/Summer 2009 
*This value represents an age group-specific average influenza rate from October 1 to 
April 30 from the 2005-06, 2006-07, and 2007-08 influenza seasons.
**Note: The scales for the 0-23 month and the ≥65 year age groups differ from other age 
groups. 
**
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Outpatient Illness Surveillance: Nationwide during week 23, 1.8% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI).  This percentage is below the national baseline of 2.4%. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
National Summary, 2008-09 and Previous Two Seasons 
*There was no week 53 during the 2006-07 and 2007-08 seasons, therefore the week 53 data point for those seasons is an average of weeks 52 and 1.
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.5% to 4.7%. One of the 
10 surveillance regions reported an ILI percentage above their region specific baseline (Region II).  
ILI decreased during week 23 in six of 10 regions compared to week 22.   
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:  The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
both seasonal influenza and pandemic influenza A (H1N1) viruses and does not measure the 
severity of influenza activity. 
 
During week 23, the following influenza activity was reported: 
? Widespread influenza activity was reported by 11 states (Arizona, Connecticut, Delaware, 
Hawaii, Maine, New Jersey, New York, Pennsylvania, Rhode Island, Utah, and Virginia). 
? Regional influenza activity was reported by Puerto Rico and six states (California, Georgia, 
Illinois, Massachusetts, Minnesota, and South Carolina). 
? Local influenza activity was reported by the District of Columbia and 13 states (Alabama, 
Colorado, Maryland, Michigan, New Mexico, North Carolina, Oklahoma, Tennessee, Texas, 
Vermont, West Virginia, Wisconsin, and Wyoming). 
? Sporadic activity was reported by 20 states (Alaska, Arkansas, Florida, Idaho, Indiana, Iowa, 
Kansas, Kentucky, Louisiana, Mississippi, Missouri, Montana, Nebraska, Nevada, New 
Hampshire, North Dakota, Ohio, Oregon, South Dakota, and Washington). 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: June 19, 2009. 
 
   
 
